Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally Advanced HER2-Positive Breast Cancer

NCT01940497 is registered in ClinicalTrials.gov with Hoffmann-La Roche as lead sponsor.

NCT NCT01940497
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01940497 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
National Phase IIIb Prospective Two-Cohort Non-Randomized, Multi-centre, Open Label Study to Assess the Safety of Subcutaneous Trastuzumab and Molecular Biomarkers in Patients With Early and Locally Advanced HER2-Positive Breast Cancer
Lead sponsor
Hoffmann-La Roche
Phase
Phase 3
Overall status
Completed
Start date
November 15, 2013
Completion date
March 27, 2018
Enrollment
240 (actual)
Sites
54

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer